Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01776658
Other study ID # SYL1001_II
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received November 14, 2012
Last updated May 22, 2015
Start date November 2012

Study information

Verified date May 2015
Source Sylentis, S.A.
Contact n/a
Is FDA regulated No
Health authority Spain: Agencia Española de Medicamentos y Productos SanitariosSpain: Comité Ético de Investigación Clínica
Study type Interventional

Clinical Trial Summary

The aim of this pilot study is to compare the analgesic effect of SYL1001 versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients of both genders

- Age = 18 years old

- Give written informed consent to participate in the study after having been informed of the study design, objectives and possible derived risks

- Common mild to moderate dry eye symptoms. Persistent daily symptoms for more than three months:

- OSDI scale: 13-30

- VAS scale: 2-7

- Ocular tests in both eyes:

- Corneal staining with fluorescein. Oxford scale > 0

- Tear Breakup Time Test: (BUT) < 10 seconds

- Schirmer test with anaesthesia < 10 mm/5min

Exclusion Criteria:

- Pregnant or breastfeeding females or those with a positive pregnancy test.

- Females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the whole study.

- Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal distress, hypertension, or infectious acute processes.

- Past history of a chronic o recurring condition that could interfere with study according to the investigator's judgement.

- Concomitant use of other drugs with analgesic activity by any route of administration at the enrolment period.

- Changes in any ocular and/or systemic concomitant medication one month prior to the study commencement and during the study development.

- Changes on the preestablished artificial tears dosage 15 days prior to the study commencement and during the study development.

- Cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen during the 6 months prior to enrolment.

- Previous history of drug hypersensitivity.

- Use of contact lenses

- Case history of drug or alcohol abuse or dependence.

- Relevant abnormal laboratory results as judged by the investigator

- Previous refractive surgery

- Participation in a clinical trial within 2 months before the enrolment visit

- Relevant ocular pathology judged by the investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
SYL1001
Ocular topical administration of SYL1001 for 10 consecutive days
Placebo
Ocular topical administration of placebo for 10 consecutive days

Locations

Country Name City State
Spain Fundación Jiménez Díaz Madrid
Spain Hospital Universitario Clínico San Carlos Madrid
Spain Instituto Oftalmológico Fernández-Vega Oviedo

Sponsors (1)

Lead Sponsor Collaborator
Sylentis, S.A.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes from Baseline in the Ocular Pain Scores on the Visual Analog Scale (VAS) and in the Ocular Discomfort Scores on the Ocular Surface Disease Index (OSDI) as a Measure of SYL1001 Analgesic Effect versus Placebo. 10 days + (4-10 days) No
Primary Simple Corneal and Conjunctival Evaluation as a Measure of Safety and Tolerability using Ophthalmic Dyes and a Slit Lamp 10 days + (4-10 days) Yes
Secondary Assessment of Adverse Events Appearance as a measure of SYL1001 tolerability 10 days + (96-240 hours) Yes
Secondary Evaluation of Vital Signs, Blood, Urine and Ocular Parameters Alterations (IOP, Visual Acuity, Anterior Segment Exploration) Possibly Related to the Investigational Product 10 days + (96-240 hours) Yes
See also
  Status Clinical Trial Phase
Completed NCT02522312 - A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients N/A
Completed NCT02597803 - Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 Phase 2/Phase 3
Completed NCT01863368 - Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining N/A
Completed NCT01753752 - Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation Phase 2
Completed NCT01753687 - Correlation of Different Signs for Assessment of Dry Eye Syndrome N/A
Completed NCT01198782 - Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Phase 4
Completed NCT01212471 - A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease Phase 3
Completed NCT01162954 - Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers Phase 1
Completed NCT00535054 - Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms N/A
Completed NCT00544713 - Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery N/A
Completed NCT00344721 - A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome N/A
Completed NCT03830359 - Efficacy, Safety of T2769 in Dry Eye Disease N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Completed NCT02758327 - Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Phase 4
Completed NCT02066051 - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD N/A
Completed NCT01970917 - Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Phase 4
Completed NCT02092207 - Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome Phase 2
Completed NCT01541891 - Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome Phase 2
Completed NCT01252121 - Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline N/A
Completed NCT00765804 - Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye Phase 2